A multicentre, open-label clinical trial to assess plasma levels and safety of bilastine in children from 2 to 5 years of age with seasonal and/or perennial allergic rhinoconjunctivitis or urticaria
Latest Information Update: 23 Feb 2023
Price :
$35 *
At a glance
- Drugs Bilastine (Primary)
- Indications Allergic rhinoconjunctivitis; Urticaria
- Focus Pharmacokinetics; Registrational
- Sponsors FAES Farma
- 23 Feb 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 28 May 2022 This trial has been completed in Lithuania, according to European Clinical Trials Database record. (end date: 21 Apr 2022).
- 18 May 2022 This trial has been completed in Slovakia (Global end date: 21 Apr 2022).